MCID: LVR013
MIFTS: 71

Liver Disease

Categories: Blood diseases, Bone diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Mental diseases, Metabolic diseases, Nephrological diseases, Oral diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Liver Disease

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 11 14 36 16 75
Liver Diseases 53 41 43 71
Liver Failure 28 53 5 71
Abnormality of the Liver 28 5
Liver Dysfunction 53 71
Liver Cell Necrosis with Hepatic Failure 33
Liver Necrosis with Hepatic Failure 33
Disorder of Bilirubin Metabolism 33
Decompensation of Liver Function 33
Disease of Bilirubin Metabolism 33
Decompensated Liver Failure 33
Decompensated Liver Disease 33
End Stage Liver Disease 33
End Stage Liver Failure 33
Liver Function Failure 33
Hepatic Decompensation 33
Hepatic Insufficiency 33
Liver Decompensation 33
Hepatic Failure Nos 33
Liver Insufficiency 33
Disorder of Liver 11
Liver Failure Nos 33
Hepatic Disorder 11
Hepatic Disease 14

Classifications:



External Ids:

Disease Ontology 11 DOID:409
ICD9CM 34 573.9
MeSH 43 D008107
NCIt 49 C3196
SNOMED-CT 68 62857009
UMLS 71 C0023895 C0085605 C0086565

Summaries for Liver Disease

MedlinePlus: 41 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary: Liver Disease, also known as liver diseases, is related to non-alcoholic fatty liver disease and fatty liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Metabolism and Nuclear receptors meta-pathway. The drugs Orange and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and kidney, and related phenotypes are Reduced mammosphere formation and liver/biliary system

Wikipedia: 75 Liver disease, or hepatic disease, is any of many diseases of the liver. If long-lasting it is termed... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Liver Disease, Severe Congenital Infantile Liver Failure Syndrome
Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2370)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 34.0 TNF NR1H4 KRT18 INS GPT GGT1
2 fatty liver disease 34.0 TNF NR1H4 KRT18 INS GPT GGT1
3 alcohol dependence 33.3 TNF SLC17A5 INS GPT GGT1 CYP2E1
4 non-alcoholic steatohepatitis 33.2 TNF NR1H4 KRT18 INS GPT CYP2E1
5 alcoholic hepatitis 33.1 TNF SLC17A5 KRT18 HGF GPT GGT1
6 alpha-1-antitrypsin deficiency 32.9 TNF SERPINA1 GPT F2 ALB AFP
7 cholangitis, primary sclerosing 32.9 TNF SERPINA1 NR1H4 GPT GGT1 F2
8 hepatitis c 32.9 SLC17A5 KRT18 GPT GGT1 F2 AFP
9 wilson disease 32.8 SERPINA1 GPT F2 ALB
10 alcohol use disorder 32.8 TNF SLC17A5 INS GPT GGT1 F2
11 progressive familial intrahepatic cholestasis 32.8 SERPINA1 NR1H4 HSD3B7 ABCB11
12 hepatic vascular disease 32.8 TNF SERPINA1 NR1H4 INS GPT F2
13 primary biliary cholangitis 32.8 TNF SLC17A5 SERPINA1 NR1H4 INS GPT
14 alcoholic liver cirrhosis 32.7 TNF INS HGF GPT GGT1 F2
15 autoimmune hepatitis 32.7 TNF SLC17A5 KRT18 GPT GGT1 F2
16 sclerosing cholangitis 32.7 TNF SERPINA1 NR1H4 GPT F2 DLAT
17 hepatic encephalopathy 32.6 TNF SLC17A5 GPT F2 ALB
18 hepatitis 32.6 TNF SLC17A5 SERPINA1 KRT18 GPT GGT1
19 hemochromatosis, type 1 32.6 SERPINA1 INS GPT FAH F2 ALB
20 type 2 diabetes mellitus 32.6 TNF SLC17A5 NR1H4 KRT18 INS HGF
21 cholestasis 32.5 SLC17A5 SERPINA1 NR1H4 HSD3B7 GPT GGT1
22 lipid metabolism disorder 32.5 TNF SLC17A5 NR1H4 INS GPT GGT1
23 hemochromatosis, neonatal 32.5 SLC17A5 GGT1
24 viral hepatitis 32.5 SLC17A5 SERPINA1 KRT18 GPT GGT1 F2
25 cholestasis, progressive familial intrahepatic, 1 32.5 NR1H4 HSD3B7 GGT1 ABCB11
26 hepatitis b 32.5 TNF SLC17A5 GPT GGT1 F2 ALB
27 bile acid synthesis defect, congenital, 2 32.5 HSD3B7 ABCB11
28 portal hypertension 32.4 TNF SLC17A5 NR1H4 GPT GGT1 F2
29 hepatorenal syndrome 32.4 GPT F2 ALB AFP
30 tyrosinemia, type i 32.3 SERPINA1 FAH AFP
31 cholangitis 32.3 TNF NR1H4 GPT GGT1 F2 DLAT
32 acute liver failure 32.3 HGF F2
33 liver cirrhosis 32.3 TNF SLC17A5 SERPINA1 MEG3 INS HGF
34 body mass index quantitative trait locus 11 32.3 TNF SLC17A5 NR1H4 INS GPT GGT1
35 budd-chiari syndrome 32.2 GPT F2 ALB AFP
36 nutritional deficiency disease 32.1 F2 ALB ADIPOQ
37 cholestasis, benign recurrent intrahepatic, 1 32.1 NR1H4 HSD3B7 ABCB11
38 hypercholesterolemia, familial, 1 32.0 NR1H4 INS GPT
39 hepatitis a 32.0 TNF SERPINA1 GPT F2 ALB AFP
40 thrombocytopenia 32.0 TNF SLC17A5 GPT GGT1 F2 ALB
41 cardiovascular system disease 32.0 TNF NR1H4 INS GGT1 ALB ADIPOQ
42 esophageal varix 32.0 SERPINA1 INS GPT F2 ALB AFP
43 gilbert syndrome 32.0 GPT F2 ALB
44 hepatocellular carcinoma 32.0 TNF SERPINA1 MEG3 KRT18 INS HGF
45 kidney disease 31.9 TNF PRKCSH INS HGF GGT1 F2
46 glucose intolerance 31.9 TNF INS GPT ALB ADIPOQ
47 atherosclerosis susceptibility 31.9 TNF INS ALB ADIPOQ
48 intrahepatic cholestasis 31.9 SLC17A5 NR1H4 HSD3B7 GPT GGT1 ALB
49 sleep apnea 31.9 TNF INS GPT ALB ADIPOQ
50 apnea, obstructive sleep 31.9 TNF INS GPT ALB ADIPOQ

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


nausea and vomiting; constipation; abdominal pain; diarrhea; hepatosplenomegaly; dyspepsia; icterus; heartburn; gastrointestinal gas; digestive system symptom; liver tender; abnormal bruising

GenomeRNAi Phenotypes related to Liver Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AFP ALB FAH GGT1 HSD3B7 KRT18

MGI Mouse Phenotypes related to Liver Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 10.21 ABCB11 ADIPOQ AFP ALB CYP2E1 FAH
2 homeostasis/metabolism MP:0005376 10.17 ABCB11 ADIPOQ AFP ALB CYP2E1 F2
3 growth/size/body region MP:0005378 10.1 ABCB11 ADIPOQ CYP2E1 F2 FAH GGT1
4 neoplasm MP:0002006 10.01 ADIPOQ AFP ALB CYP2E1 FAH KRT18
5 cellular MP:0005384 9.97 ADIPOQ ALB F2 FAH GGT1 HGF
6 behavior/neurological MP:0005386 9.8 ABCB11 ADIPOQ AFP CYP2E1 DLAT F2
7 mortality/aging MP:0010768 9.58 ABCB11 ADIPOQ ALB CYP2E1 DLAT F2

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 764)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 4
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
4
Alogliptin Approved Phase 4 850649-61-5 11450633
5
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
6
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
7
Iron Approved Phase 4 7439-89-6 29936
8
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
9
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
10
Ethanolamine oleate Approved Phase 4 2272-11-9
11
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
12
Pravastatin Approved Phase 4 81093-37-0 54687
13
Rifampicin Approved Phase 4 13292-46-1 135512673 5381226 135900090
14
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
15
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
16
Insulin aspart Approved Phase 4 116094-23-6 16132418
17
Insulin detemir Approved Phase 4 169148-63-4 16137271
18
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
19
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
20
Promethazine Approved, Investigational Phase 4 60-87-7 4927
21
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
22
Adenosine Approved, Investigational Phase 4 58-61-7 60961
23
Gliclazide Approved Phase 4 21187-98-4 3475
24
Glimepiride Approved Phase 4 93479-97-1 3476
25
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 2826718
26
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
27
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
28
Desflurane Approved Phase 4 57041-67-5 42113
29
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456 5824
30
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
31
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
32
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
33
Phentermine Approved, Illicit Phase 4 122-09-8 4771
34
Montelukast Approved Phase 4 158966-92-8 5281040
35
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
36
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
37
Deferiprone Approved Phase 4 30652-11-0 2972
38
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
39
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
40
Nevirapine Approved Phase 4 129618-40-2 4463
41
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
42
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
43
Lactulose Approved Phase 4 4618-18-2 11333
44
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
45
Dapagliflozin Approved Phase 4 461432-26-8 9887712
46
Oprelvekin Approved, Investigational Phase 4 145941-26-0
47
Remifentanil Approved Phase 4 132875-61-7 60815
48
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
49
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
50
Temocillin Approved, Investigational Phase 4 66148-78-5 13712660

Interventional clinical trials:

(show top 50) (show all 2634)
# Name Status NCT ID Phase Drugs
1 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease Unknown status NCT04718051 Phase 4 Shen Pu Yang Gan Wan;Placebo
4 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
5 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
6 The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial - Unknown status NCT04465032 Phase 4
7 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
8 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Unknown status NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
9 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
11 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
12 Somatostatin as Inflow Modulator in Adult-to-adult Living Donor Liver Transplantation: a Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT04107428 Phase 4 Somatostatin;Placebo
13 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
14 A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
15 Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
16 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
17 The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
18 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
19 Use of HA 330-II for Hemofiltration in Patients With Acute Liver Failure as a Bridge to Liver Transplantation: Clinical Evaluation Protocol. Unknown status NCT04243655 Phase 4 Standard medical treatment (SMT)
20 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
21 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
22 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
23 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Unknown status NCT03198572 Phase 4 Placebo;Berberine
24 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Unknown status NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
25 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Unknown status NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
26 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
27 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Unknown status NCT02764671 Phase 4
28 Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation: A Randomized Controlled Study Unknown status NCT03522688 Phase 4 Dexmedetomidine
29 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
30 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients Unknown status NCT02882113 Phase 4 Advagraf
31 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
32 Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease Completed NCT00862446 Phase 4 Omegaven
33 Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection Completed NCT00799851 Phase 4 cyanoacrylate injection
34 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
35 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
36 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation Completed NCT00402402 Phase 4
37 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
38 A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine the Efficacy and Safety of Pravastatin 80 mg Administered Once Daily to Hypercholesterolemic Subjects With Chronic, Well Compensated Liver Disease Completed NCT00529178 Phase 4 Pravastatin
39 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
40 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
41 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
42 CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver Disease - A Prospective, Randomized, Multicenter Trial. Completed NCT00206076 Phase 4 mycophenolate mofetil
43 Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation. Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
44 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
45 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Completed NCT02366845 Phase 4
46 A Double-Blind, Randomized, Multicenter Trial Examining the Efficacy of Biphenyl Dimethyl Dicarboxylate Combined With Garlic Oil in Patients With Transaminase Elevated Chronic Liver Disease Completed NCT02347319 Phase 4 Pennel;Legalon;Placebo
47 Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
48 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
49 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
50 A Randomized Study to Compare the Efficacy of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Patients With Non-alcoholic Fatty Liver Disease Using (IL6 and CCL2) as a Predictors of Non-alcoholic Steatohepatitis Completed NCT04977661 Phase 4 Vitamin E;Ursodeoxycholic acid;Pentoxifylline

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alglucerase
imiglucerase
Medium chain triglycerides

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Liver Failure 28
2 Abnormality of the Liver 28

Anatomical Context for Liver Disease

Organs/tissues related to Liver Disease:

MalaCards : Liver, Bone Marrow, Kidney, Skin, Skeletal Muscle, Bone, Spleen

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 52475)
# Title Authors PMID Year
1
Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment. 41
36217101 2022
2
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. 41
36352054 2022
3
Plant-Derived Lactobacillus paracasei IJH-SONE68 Improves the Gut Microbiota Associated with Hepatic Disorders: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial. 41
36364756 2022
4
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. 53 62
20371660 2010
5
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 53 62
20363656 2010
6
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. 53 62
19942238 2010
7
The PXR is a drug target for chronic inflammatory liver disease. 53 62
20416375 2010
8
Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. 53 62
20490434 2010
9
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. 53 62
20503453 2010
10
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 53 62
20415685 2010
11
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? 53 62
20406065 2010
12
Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. 53 62
20473736 2010
13
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. 53 62
20200515 2010
14
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 53 62
19881359 2010
15
Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 53 62
19946731 2010
16
Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. 53 62
19770674 2010
17
Natural anticoagulants can be useful predictors of severity in chronic liver disease. 53 62
20019598 2010
18
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. 53 62
20335584 2010
19
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. 53 62
20093562 2010
20
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 53 62
19931264 2010
21
A novel c.592-4_c.592-3delTT mutation in DGUOK gene causes exon skipping. 53 62
19900589 2010
22
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 53 62
20150538 2010
23
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. 53 62
19839004 2010
24
Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 53 62
20170533 2010
25
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 53 62
20176643 2010
26
Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 53 62
19817962 2010
27
Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. 53 62
19829123 2010
28
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 53 62
19940802 2010
29
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. 53 62
19950230 2010
30
The role of cytokines in non-alcoholic fatty liver disease. 53 62
20460908 2010
31
Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. 53 62
20043871 2010
32
Animal models for hepatitis C and related liver disease. 53 62
20156300 2010
33
Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. 53 62
19910932 2010
34
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. 53 62
19793164 2010
35
Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. 53 62
19687773 2009
36
Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. 53 62
19948621 2009
37
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 53 62
19769633 2009
38
Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease. 53 62
19925451 2009
39
Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. 53 62
19474742 2009
40
Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. 53 62
19525859 2009
41
Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. 53 62
19278843 2009
42
The unfolding clinical spectrum of POLG mutations. 53 62
19578034 2009
43
Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications. 53 62
19706148 2009
44
Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. 53 62
19788461 2009
45
Albumin dialysis in liver failure: comparison of molecular adsorbent recirculating system and single pass albumin dialysis--a retrospective analysis. 53 62
19788459 2009
46
Increase of octanoate concentrations during extracorporeal albumin dialysis treatments. 53 62
19788462 2009
47
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. 53 62
19422483 2009
48
Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. 53 62
19624771 2009
49
Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. 53 62
19560784 2009
50
Hemodynamic effects of albumin dialysis in patients with liver failure: for better or for worse? 53 62
19788454 2009

Variations for Liver Disease

ClinVar genetic disease variations for Liver Disease:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYOM1 NM_003803.4(MYOM1):c.3260G>A (p.Trp1087Ter) SNV Likely Pathogenic
804425 rs374670754 GRCh37: 18:3116372-3116372
GRCh38: 18:3116374-3116374
2 YARS1 NM_003680.4(YARS1):c.611A>C (p.Tyr204Ser) SNV Uncertain Significance
986742 rs1217293329 GRCh37: 1:33256836-33256836
GRCh38: 1:32791235-32791235

Expression for Liver Disease

Search GEO for disease gene expression data for Liver Disease.

Pathways for Liver Disease

Pathways related to Liver Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 ABCB11 ADIPOQ ALB CYP2E1 DLAT FAH
2
Show member pathways
12.46 TNF SERPINA1 NR1H4 HGF GGT1 ABCB11
3
Show member pathways
12.39 NR1H4 INS HSD3B7 ALB ABCB11
4
Show member pathways
12.02 SERPINA1 PRKCSH F2 ALB AFP
5
Show member pathways
11.99 NR1H4 HSD3B7 ALB ABCB11
6 11.68 SERPINA1 INS HGF ALB AFP
7 11.45 TNF SERPINA1 HGF
8 11.12 NR1H4 CYP2E1 ABCB11
9
Show member pathways
10.89 INS F2 ALB AFP
10 10.68 TNF NR1H4 INS CYP2E1 ADIPOQ
11 10.64 TNF NR1H4

GO Terms for Liver Disease

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.93 TNF SERPINA1 INS HGF GPT GGT1
2 endoplasmic reticulum lumen GO:0005788 9.4 SERPINA1 PRKCSH INS F2 ALB AFP

Biological processes related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to bacterium GO:0009617 9.91 TNF SLC17A5 CYP2E1 ADIPOQ
2 response to ethanol GO:0045471 9.86 ABCB11 ADIPOQ CYP2E1 TNF
3 acute-phase response GO:0006953 9.8 SERPINA1 INS F2
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.56 TNF INS HGF F2
5 carbohydrate transmembrane transport GO:0034219 9.46 SLC17A5 ABCB11
6 glucose metabolic process GO:0006006 9.23 TNF INS DLAT ADIPOQ

Sources for Liver Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....